10,305 Results

Five-year study shows SRT-100 benefits patients with non-melanoma skin cancer/- Sensus Healthcare

 Added 13 hours ago

Sensus Healthcare announced topline results from a five-year retrospective study of non-melanoma skin cancer (NMSC) patients treated with Superficial Radiation...

FDA approves TransPyloric Shuttle device for obesity.- BAROnova

 Added 13 hours ago

BAROnova announced that the FDA has approved the TransPyloric Shuttle (TPS) Device, a non-surgical weight loss solution for adult individuals...

FDA expands approval for KardiaMobile to include bradycardia and tachycardia detection.- AliveCor

 Added 13 hours ago

AliveCor announced two additional FDA 510(k)-cleared indications, making KardiaMobile the only consumer ECG device in the world with FDA-clearance to...

Keytruda and Inlyta approved by FDA to treat first line renal cell carcinoma

 Added 1 day ago

Merck Inc., announced that the FDA has approved Keytruda, Merck’s anti-PD-1 therapy, in combination with Inlyta (axitinib), a tyrosine kinase...

FDA approves first medical device, Monarch external Trigeminal Nerve Stimulation System to treat ADHD

 Added 13 hours ago

The FDA permitted marketing of the first medical device to treat attention deficit hyperactivity disorder (ADHD). The prescription-only device, called...

Successful COAST-X Phase III study of Taltz for the treatment of non-radiographic axial spondyloarthritis

 Added 1 day ago

Eli Lilly and Company announced that Taltz (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase...

ECO 2019 | Find out more

 Added 1 day ago

ECO 2019 | Find out more

Soligenix reports enrollment stage for its pivotal phase III trial of SGX 942 for oral mucositis in head and neck cancer

 Added 4 days ago

Soligenix announced that it has reached a significant milestone in the Phase III clinical study (the "DOM-INNATE" study) for SGX...

Results of long term study of tanezumab in patients with osteoarthritis

 Added 4 days ago

Pfizer Inc. and Eli Lilly and Company announced top-line results from a Phase III study evaluating tanezumab 2.5 mg and...

Load more